Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986218 +/- Nivolumab + Docetaxel in mCRPC
NCT05169684Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of BMS-986218 in metastatic castration-resistant prostate cancer (mCRPC) (6 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of Participants With Treatment Related Adverse Events up to 22 months, Number of Participants With Treatment Related Serious Adverse Events up to 22 months and 3 more. Started Feb 2022; status: terminated.
02
Drugs
BMS-986218
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05169684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05169684.